# Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients

> **NCT04548440** · PHASE2 · COMPLETED · sponsor: **Sun Yat-Sen University Cancer Center** · enrollment: 50 (actual)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Nab paclitaxel
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT04548440
- **Lead sponsor:** Sun Yat-Sen University Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-31
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2025-06-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04548440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04548440, "Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04548440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*